Background: Apixaban and rivaroxaban are the most commonly prescribed direct oral
anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety …

Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …

No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …